.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Queensland Health
Cipla
UBS
Chubb
Johnson and Johnson
Covington
Colorcon
Mallinckrodt

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011153

« Back to Dashboard

NDA 011153 describes MEDROL, which is a drug marketed by Pharmacia And Upjohn and is included in three NDAs. It is available from seven suppliers. Additional details are available on the MEDROL profile page.

The generic ingredient in MEDROL is methylprednisolone. There are forty drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the methylprednisolone profile page.

Summary for 011153

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Inflammatory Bowel Disease Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 011153

Medical Subject Heading (MeSH) Categories for 011153

Suppliers and Packaging for NDA: 011153

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MEDROL methylprednisolone TABLET;ORAL 011153 NDA Pharmacia and Upjohn Company LLC 0009-0020 0009-0020-01 100 TABLET in 1 BOTTLE (0009-0020-01)
MEDROL methylprednisolone TABLET;ORAL 011153 NDA Pharmacia and Upjohn Company LLC 0009-0022 0009-0022-01 25 TABLET in 1 BOTTLE (0009-0022-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength16MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Medtronic
Boehringer Ingelheim
McKinsey
Healthtrust
UBS
Federal Trade Commission
Fuji
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot